SPI Pharma & Inimmune to Develop &Commercialize Vaccine Adjuvant
17 Jul 2024 //
PR NEWSWIRE
INIMMUNE Reports Successful Phase 1 For Allergy Treatment INI-2004
15 May 2024 //
PR NEWSWIRE
Inimmune Collaborates with Boston Children`s Hospital to Develop Novel Adjuvants
24 Oct 2023 //
PR NEWSWIRE
Inimmune CSO Jay Evans to present an update on clinical stage programs
28 Sep 2023 //
PR NEWSWIRE
Inimmune announces First Subject Dosed in First-in-Human Ph 1 Trial of INI-2004
02 Aug 2023 //
PR NEWSWIRE